Elevar Therapeutics and Inceptua partner to commercialize Apealea®

By Akshay Kedari  | Date: 2020-12-29

Elevar Therapeutics and Inceptua partner to commercialize Apealea®

According to reliable sources, U.S.-based fully integrated biopharmaceutical company, Elevar Therapeutics Inc., has signed an exclusive agreement with Inceptua Group for the commercialization and distribution of its non-cremophor based paclitaxel treatment Apealea® in Europe. 

For the uninitiated, Elevar Therapeutics is a Utah-headquartered organization that focuses on offering medical services to patients who have inadequate or limited therapeutic options. Their patent treatment Apealea® is a water-soluble, intravenously injectable chemotherapy agent that is primarily used to treat ovarian cancer as well as other solid tumors.

Reportedly, the recent collaboration is aimed at leveraging Inceptua’s capabilities in oncology development as well as orphan treatments to strengthen the presence of Apealea® in the European market and optimize the value of its portfolio on a global level.

As per the contract, Inceptua will be granted exclusive rights for the distribution and commercialization of the drug across Europe. However, these rights do not permit the administration in Nordic countries including Iceland, Sweden, Norway, Finland, and Denmark.

Stefan Fraenkel, Chief Executive Officer of Inceptua, was reported saying that the company has observed great potential in Apealea® for treatment of ovarian cancer among patients who have a low tolerance for paclitaxel formulated with cremophor. The organization’s established sales force, vast market access capabilities, and robust distribution networks will bolster the commercialization of the treatment throughout Europe, he added.

It is to be noted that Apealea® was granted marketing authorization by regulatory authorities for its administration in the European Economic Area in November 2018, in combination with carboplatin for treating adult patients diagnosed with platinum-sensitive epithelial ovarian cancer. The treatment has recently been granted Orphan Drug Designation by the U.S. FDA (Food and Drug Administration), as cited by credible sources.

About Inceptua Group

Established in 1997, Inceptua focuses on delivering products and services for clinical trials and providing medication for various patient programs. The company’s primary objectives include offering customer-centric services at all stages of a drug lifecycle, facilitating access to unlicensed medicines, and providing an international commercialization platform for pharmaceutical as well as biopharmaceutical products.  

Source credits –

https://www.prnewswire.com/news-releases/elevar-therapeutics-announces-licensing-agreement-with-inceptua-group-for-commercialization-of-apealea-paclitaxel-micellar-in-europe-301198507.html

About Author

Akshay Kedari     aeresearch.net

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More >>

More News By Akshay Kedari

Fitbit faces privacy complaints in EU over alleged unlawful data exports

Fitbit faces privacy complaints in EU over alleged unlawful data exports

By Akshay Kedari

Fitbit, a Google company, is reportedly facing a series of privacy complaints within the European Union. These complaints revolve around allegations that the company is engaging in unlawful exporting of user data, thereby violating the EU's strin...

Social network X makes API changes impacting developers & enterprise clients

Social network X makes API changes impacting developers & enterprise clients

By Akshay Kedari

Social network X, previously known as Twitter, has reportedly unveiled more modifications that involve the retirement of certain legacy API endpoints. The company implemented adjustments to its API pricing in March, resulting in elevated costs for...

Zapata AI and IonQ joins hands to push boundaries of Generative AI

Zapata AI and IonQ joins hands to push boundaries of Generative AI

By Akshay Kedari

Zapata AI, a software enterprise dedicated to addressing intricate computational challenges, has reportedly unveiled a strategic partnership with IonQ, a leading figure in quantum computing hardware and commercial quantum application advancement. The...

Meta unveils AudioCraft for audio & music creation using Generative AI

Meta unveils AudioCraft for audio & music creation using Generative AI

By Akshay Kedari

The tech giant Meta has reportedly introduced AudioCraft, a framework capable of generating high-quality audio and music based on short text prompts. The AudioCraft framework aims to simplify the use of generative models for audio by providing a c...

GSK Pharma reports 11% surge in Q1 profit fueled by Vaccine Demand

GSK Pharma reports 11% surge in Q1 profit fueled by Vaccine Demand

By Akshay Kedari

GlaxoSmithKline Pharmaceuticals, the Indian arm of GSK plc based in the UK, reportedly recorded an 11% increase in its first-quarter profit, driven by robust demand for its vaccines. According to the company's statement, the consolidated profi...